- GHRP-2 has more published human dosing data behind it than the other peptides in its class. Japan approved it as a diagnostic test in 2004, validated across 84 clinical sites and 126 patients.
- Growth hormone output levels off at about 100 mcg (roughly 1 mcg per kg of body weight). The stress hormones it also releases do not level off at the same point, so 200 to 300 mcg buys you more cortisol, not more growth hormone.
- At clinical doses, GHRP-2 produces a cortisol response the size of a deliberate clinical stress-test injection. Ipamorelin, at doses releasing comparable growth hormone, produces almost none.
- Every pharmaceutical company that took GHRP-2 into therapeutic trials dropped it. The reason in the literature was that cortisol response, not any acute safety problem.
- The receptor GHRP-2 works through is the same one ipamorelin uses. If ipamorelin did nothing for you because that receptor is the bottleneck, GHRP-2 will not get past it either.
Every pharmaceutical company that ran GHRP-2 through therapeutic trials abandoned it. Not for acute safety reasons. Not because it failed to work. They abandoned it because it also switches on the body's stress-hormone axis, releasing cortisol alongside growth hormone, and at the doses needed for meaningful growth hormone output that made it unsuitable for long-term use. Japan approved it in 2004, but only as a single-injection diagnostic test for pituitary function. No major market has ever approved GHRP-2 for therapy. The peptide community runs it at 3 to 10 times the diagnostic dose on multi-month cycles, extrapolating from an approval that was explicitly not for what they are using it for.
That context does not mean GHRP-2 is dangerous or useless. It means the dosing logic requires more care than a standard GHRP guide provides. This article covers what the 30-year human trial record actually shows, why the 200 to 300 mcg protocol most guides recommend works against itself, and the one thing worth checking in your DNA before you commit to a cycle.
The number of clinical sites Japan's medicines regulator required to validate the GHRP-2 diagnostic test before approving it in October 2004. The trial enrolled 126 patients across those sites. The approved dose: 100 mcg into a vein, roughly 1 mcg per kg of body weight. A 2022 Journal of the Endocrine Society analysis confirmed the test performs comparably to insulin tolerance testing, the long-standing reference method for diagnosing pituitary disorders. No other peptide in this class has been through an equivalent regulatory validation in any major market.
Think of this family of peptides as a power dial with a stress-hormone dial wired to it. Hexarelin sits at one end: most growth hormone, biggest cortisol spike, receptor stops responding within about a week. Ipamorelin sits at the other: moderate output, almost no cortisol, runs cleanly for 8 to 12 weeks. GHRP-2 sits between them. It releases meaningfully more growth hormone than ipamorelin, it releases real cortisol with it, and its receptor tires faster than ipamorelin's but slower than hexarelin's. Choosing it over ipamorelin means accepting that trade deliberately.
Does GHRP-2 Actually Spike Cortisol? The Study That Settled This in 1997
The most important paper to read before starting GHRP-2 was published in Peptides in 1997. Arvat and colleagues gave healthy adults GHRP-2 into a vein at 1 to 2 mcg per kg of body weight. At both doses, the cortisol response, and the pituitary signal that drives it, matched what you get from injecting synthetic CRH. CRH is the body's own cortisol-releasing hormone, and clinicians inject the synthetic version precisely when they want to provoke the stress axis on purpose for a diagnostic test.
In practical terms: one injection of GHRP-2 at research doses provokes your stress axis about as hard as a clinical stress test does. That is not a footnote. It happens every time you dose.
"At doses producing equivalent GH release, GHRP-2 and hexarelin induced ACTH and cortisol responses comparable to those produced by hCRH administration, whereas ipamorelin had no significant effect on plasma ACTH or cortisol above baseline at any dose tested."
Arvat E et al., Peptides, 1997: head-to-head comparison of how selectively each of these peptides acts, and how much each provokes the stress axis
This is the "well, actually" finding that competitor guides skip over. The widespread belief in peptide communities is that GHRP-2 is ipamorelin but stronger. In reality, ipamorelin was engineered specifically to strip out the stress-hormone release that GHRP-2 carries. A 1998 paper in Regulatory Peptides coined the term "selective growth hormone secretagogue" for ipamorelin precisely because it broke the pattern of stress-hormone release seen in every earlier peptide of this type, GHRP-2 included. Ipamorelin's clean cortisol profile is not a lucky accident of its structure. It was the design brief, and GHRP-2 was the problem the designers set out to solve.
For a healthy person with normal cortisol and no history of stress-axis trouble, the cortisol released by one to three injections a day is manageable. It becomes a genuine concern in three situations: cortisol that is already running high, other cortisol-raising compounds in the same protocol, and carrying the T version of FKBP5 at rs1360780, which slows the switch that shuts a cortisol surge back off and so stretches every spike out. If you are unsure whether the receptor these peptides need is working for you at all, the non-responder article covers that question directly.
Why Going Above 100 mcg Gives You More Cortisol, Not More GH
This is the gap no standard GHRP-2 guide addresses. The Arvat 1997 data showed something most dosing recommendations ignore: growth hormone release levels off at around 1 mcg per kg, which for an average adult is roughly 70 to 100 mcg per injection. The cortisol side does not level off there. It keeps climbing as the dose rises.
So going from 100 mcg to 200 or 300 mcg buys you a substantially bigger cortisol hit and very little extra growth hormone. You are on the steep part of one curve and the flat part of the other. The 200 to 300 mcg protocols circulating in peptide communities maximise the wrong one.
That mismatch is why pharmaceutical companies concluded GHRP-2 could not be used long term. The dose that produced useful growth hormone was also the dose that provoked the stress axis hard. There was no window in between. Ipamorelin solved the problem at the level of receptor design. GHRP-2 never had a chemical answer to it.
GHRP-2 Dosage Chart: What Human Research Actually Used
Human research protocols clustered GHRP-2 dosing in a narrow range that maps directly to the pharmacology above. Less of a dose injected under the skin reaches the bloodstream than one given into a vein, which is why the injected-under-the-skin protocols run slightly above the Japanese diagnostic dose. Growth hormone peaks 15 to 30 minutes after the injection either way.
| Use Case | Dose per Injection | Frequency | Min. Gap | Cycle |
|---|---|---|---|---|
| Diagnostic standard (IV, clinical) | 100 mcg (1 mcg/kg) | Single dose | N/A | Single |
| GH pulse augmentation (subcutaneous) | 100 mcg | 1x daily, pre-sleep | 8+ hours from prior GH stimulus | 7-10 days on, 3-4 weeks off |
| Full secretagogue protocol (subcutaneous) | 100-150 mcg | 3x daily | 3+ hours between injections | 7-10 days on, 3-4 weeks off |
| Stack with GHRH analog | 100 mcg | 1-2x daily | 3+ hours between injections | Per GHRH analog cycle length |
Notice that the dose range stays at 100 to 150 mcg even for the full secretagogue protocol. This is not a conservative arbitrary choice. It reflects the GH saturation point. If you want more total GH output per day, the correct variable to adjust is injection frequency (up to 3x daily with 3-hour gaps), not dose size. Three injections of 100 mcg per day gives you more total GH exposure than two injections of 200 mcg per day, with meaningfully less cumulative cortisol load per unit of GH produced.
Why Dosing Frequency Matters More Than Dose Size
The 3-hour minimum gap between injections is the most important rule in any GHRP-2 protocol, and it applies to this whole class of peptide for the same reason. Inject before the receptor has recovered from the last dose and you are dosing into a receptor that is still busy. It will bind the peptide, but the signal it sends onward is muted, and each successive injection in a tight cluster delivers less than the one before. Nobody has published a clean number for how much less.
The 3-hour gap mirrors your own biology. Your body releases growth hormone in bursts roughly three hours apart, because that is how long it takes for somatostatin, the brake signal from your hypothalamus, to fade and the pituitary to become responsive again. Dose more often than that and you are fighting the same brake that governs your natural output.
For the full recovery timeline across an off-cycle, see the GH receptor reset guide. GHRP-2 tires the receptor faster than ipamorelin because it grips it more tightly: more of the receptor is occupied per dose, so the ceiling arrives sooner. The 7 to 10 day useful window follows from that, and is not an arbitrary limit.
GHRP-2 vs Ipamorelin vs GHRP-6: A Straight Comparison on the Variables That Matter
Most GHRP comparisons treat GH output as the only relevant variable and rank the peptides on that axis. The actual decision matrix requires four variables: GH output, cortisol effect, appetite effect (which matters operationally for users in caloric deficit), and how fast the receptor desensitizes. Here is where each compound actually sits on all four.
GH output: GHRP-2 is meaningfully higher per injection. Cortisol: GHRP-2 provokes a spike the size of a clinical stress test; ipamorelin produces almost none at comparable doses. Appetite: neither does much. Receptor fatigue: GHRP-2 stops being useful within 7 to 10 days; ipamorelin holds for 8 to 12 weeks. Legal availability: both sit outside the FDA's approved compounding list, and the position has shifted through 2026.
GH output: comparable, with GHRP-2 slightly higher in head-to-head trials. Cortisol: both provoke the stress axis, GHRP-2 slightly harder per the Arvat data. Appetite: GHRP-6 is in a class of its own for hunger, because it also acts on the hunger circuits in the hypothalamus that GHRP-2 leaves alone. Receptor fatigue: similar. That appetite difference matters in practice: GHRP-6 is a problem if you are eating in a deficit and GHRP-2 is not. For users who tolerate the cortisol effect and want to avoid the GHRP-6 hunger drive, GHRP-2 is the cleaner option of the two.
| Variable | GHRP-2 | Ipamorelin | GHRP-6 |
|---|---|---|---|
| Relative GH output per dose | High | Moderate | Moderate-High |
| Cortisol co-stimulation | Significant, matching a clinical stress test | Near zero | Moderate-significant |
| Appetite stimulation | Minimal | Minimal | Strong, via the brain's hunger circuits |
| Useful cycle window | 7-10 days | 8-12 weeks | 7-10 days |
| Off-cycle recovery | 3-4 weeks | 2-4 weeks | 3-4 weeks |
| FDA 503A injectable status (2026) | Not on the approved list | Category 1 (expected) | Unreviewed |
| Regulatory anchor | Japan diagnostic approval 2004 | None | None |
Does GHRP-2 Build Muscle? What the Human Data Actually Shows
The honest answer: the body composition evidence in healthy, well-nourished adults is essentially absent. There is no large randomized controlled trial measuring lean mass or fat mass in healthy adults on GHRP-2. Every body-composition claim in the peptide community is an extrapolation from the well-documented fact that GHRP-2 reliably raises GH and IGF-1, combined with the well-documented fact that growth hormone and IGF-1 build muscle and break down stored fat. The reasoning is sound. It is not evidence.
The most clinically significant case in the published record appears in a 2015 paper in the Journal of Cachexia, Sarcopenia and Muscle. A severely emaciated anorexia nervosa patient received intranasal GHRP-2 for one year under clinical supervision. The result was progressive improvement in body weight, lean mass measurements, GH levels, and IGF-1 levels across the treatment period. That is meaningful evidence that GHRP-2 can drive tissue building when starvation has shut the growth hormone system down. It says nothing about a healthy, well-fed adult with normal output.
The downstream tissue response to whatever GH elevation GHRP-2 produces is governed by your receptor genetics, not by the peptide itself. GHR is the receptor growth hormone lands on, and its common shortened version (d3) may turn a burst into IGF-1 more readily. IGF-1R is the next receptor along, the one that sets how strongly your tissues answer that IGF-1. GHRP-2 pulls the trigger; how loudly the shot lands is inherited. For a breakdown of those genetic variables, see the IGF-1 receptor genetics guide.
GHRP-2 and CJC-1295: Why the Stack Works and How to Build It
The most common GHRP-2 search query after "GHRP-2 dosage" is "GHRP-2 CJC-1295 stack," and for good reason. Combining a GHRP with a GHRH analog is the most evidence-supported approach to maximizing GH output from secretagogue use. The logic is mechanistic and well-established: CJC-1295 loads the pituitary cells that store growth hormone, filling them ready to fire. GHRP-2 then pulls the trigger. The combination produces more than the sum of the two.
The GHRH analog also partially compensates for GHRP-2's faster receptor desensitization. When the receptor GHRP-2 uses starts to tire, the other pathway is still working and keeps those pituitary cells loaded for the next pulse. This is why stack cycles can run slightly longer than GHRP-2-only protocols without losing all meaningful GH output.
The cortisol co-stimulation is not changed by the GHRH component. CJC-1295 uses a completely different receptor and does not touch the stress axis at standard doses. GHRP-2's cortisol spike happens regardless of whether CJC-1295 is in the stack. If the cortisol issue is a concern for you, adding CJC-1295 does not reduce it. The solution to the cortisol issue is switching from GHRP-2 to ipamorelin in the GHRP slot, not adding a GHRH analog.
The adult GH-sufficiency cutoff from the Japanese multicenter GHRP-2 diagnostic trial. A response above 9 ng/mL after 100 mcg into a vein rules out growth hormone deficiency in adults per the 2022 Journal of the Endocrine Society validation analysis. This is the only regulatory-validated outcome anchor for GHRP-2 dosing in humans. Community protocols typically target IGF-1 elevation rather than acute GH peak, but the 100 mcg diagnostic dose gives you the calibration reference point for what that dose actually produces in human GH output.
Who Should Consider GHRP-2 and Who Should Not
GHRP-2 makes sense for a narrow profile: someone who has completed at least one ipamorelin cycle and confirmed on bloodwork that their IGF-1 actually moved, which proves the receptor works, and who wants a short high-intensity window rather than a sustained long-cycle approach, and has no history of cortisol dysregulation. That is not most peptide users. It is a minority of experienced users at a specific protocol stage.
GHRP-2 does not make sense for: first-time GHRP users, anyone whose cortisol is already high or who shows the early signs of a stressed system (fat gathering around the middle, broken sleep, persistent anxiety), anyone on steroid medication, and anyone ipamorelin did nothing for. That last one is the point most people miss. A poorly working version of the GHSR receptor blocks every peptide that needs it, GHRP-2 included. Switching between them does not change the receptor. The answer in that case is a growth hormone releasing hormone peptide, which goes in a different door.
The food timing rule also deserves direct treatment, because most guides state it without explaining it. Fast for 30 to 45 minutes before and after your GHRP-2 injection. The mechanism: blood sugar and circulating fats from a recent meal raise your levels of somatostatin, the brake signal your hypothalamus uses to shut growth hormone release down. Inject after eating and the peptide still binds its receptor, but the brake is on and the resulting pulse is smaller. Fasting here is not really about insulin. It is about releasing the brake before you press the accelerator.
If you want to see whether that receptor works for you, and the rest of the variants that govern growth hormone response, visit the GHRP-2 peptide profile page or upload your raw DNA file at peptidesdna.com/upload. Knowing your receptor status before committing to a GHRP-2 cycle removes the largest single variable that determines whether any of this is worth doing.
Verdict: GHRP-2 carries the deepest human trial record of its class. It is not simply a stronger ipamorelin. The extra growth hormone is real. So is the cortisol, and so is how quickly the receptor tires. The dose validated in humans is 100 mcg, not 200 to 300, and going above it adds cortisol without adding proportional growth hormone, which is the curve pharmaceutical researchers mapped before walking away from the compound. If the receptor works for you, your cortisol is normal, and you want a short high-intensity window, 100 mcg three times daily with 3-hour gaps over 7 to 10 days is coherent. For everyone else, ipamorelin with a growth hormone releasing hormone peptide is cleaner and lasts far longer. Check your genetics first at peptidesdna.com/upload, or if you have never had your DNA read, we will point you to a testing partner.
Frequently asked questions
What is the correct GHRP-2 dosage?
Human research and the Japanese regulatory data point to 100 mcg per injection as the dose where GH output approaches saturation. Higher doses (200-300 mcg) do not produce proportionally more GH but do produce more ACTH and cortisol. For subcutaneous use, 100 mcg per injection dosed 1 to 3 times daily with minimum 3-hour gaps between injections is the protocol that respects both the GH dose-response curve and receptor desensitization kinetics.
How is GHRP-2 different from ipamorelin?
The cortisol response. At standard doses GHRP-2 provokes the stress axis about as hard as a deliberate clinical stress test does. Ipamorelin was engineered specifically to avoid that while releasing comparable growth hormone. GHRP-2 also tires its receptor faster, giving a useful window of 7 to 10 days against ipamorelin's 8 to 12 weeks. Growth hormone per injection is higher with GHRP-2.
How long can you run GHRP-2 before it stops working?
Meaningful GH response from GHRP-2 attenuates within 7 to 10 days of continuous dosing. GHRP-2 desensitizes faster than ipamorelin because its receptor affinity is higher, meaning more receptor occupancy per dose and a quicker path to the refractory ceiling. A 3 to 4 week off-period restores receptor sensitivity. Running past 10 days produces diminishing GH output while the cortisol co-stimulation continues at the same level.
Can you stack GHRP-2 with CJC-1295?
Yes. Combining GHRP-2 with a GHRH analog like CJC-1295 produces synergistic GH output because the two peptides act on different receptors. CJC-1295 loads the pituitary cells that store growth hormone; GHRP-2 fires them. The stack partially compensates for GHRP-2's faster receptor desensitization. The cortisol co-stimulation from GHRP-2 is unaffected by the GHRH component. If cortisol is a concern, replace GHRP-2 with ipamorelin in the GHRP slot rather than removing the GHRH analog.
Does GHRP-2 cause hunger like GHRP-6?
No. GHRP-6 drives hunger because it also acts on the appetite circuits in the hypothalamus. GHRP-2 does not touch them. Clinical reports and user experience consistently describe GHRP-2 as appetite-neutral to mildly appetite-suppressive. For users managing caloric intake, this is a practical advantage of GHRP-2 over GHRP-6.
Is GHRP-2 legal to buy in the United States?
As of mid-2026, GHRP-2 sits outside the FDA's approved compounding list, which means licensed compounding pharmacies cannot legally compound it for subcutaneous use. This places it in a weaker regulatory position than ipamorelin, though neither is currently on the approved compounding list. GHRP-2 is also prohibited at all times under the 2026 WADA Prohibited List (Section S2) for competitive athletes.
Why do you need to fast before a GHRP-2 injection?
Blood sugar and circulating fats from a recent meal raise somatostatin, the brake signal your hypothalamus uses to shut growth hormone release down. Inject after eating and the peptide still binds its receptor and the pituitary still gets the message, but the brake is on and the pulse comes out smaller. Fasting 30 to 45 minutes either side of the injection takes the brake off.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.